leading to either obliteration or filling defects within the nodes; even large defects are sometimes almost impossible to assess accurately at the initial examination. McDonald (1969) stressed that lymphangiography is no substitute for histology, but adequate biopsy confirmation or denial of suspected findings is not always readily forthcoming. Furthermore, a gland reacting to the presence of Lipiodol within it must surely pose some problems to the histologist in the doubtful case.
Nevertheless, lymphangiography is undoubtedly of great potential value in most cases of lymphoreticular disease and in some cases of carcinoma in particular sites. The interpretative difficulties should be well recognized and an attitude of watchful expectancy should be adopted in all doubtful appearances. Confirmatory microscopy of suspicious findings is clearly desirable as a means of increasing one's diagnostic accuracy rate.
Mr Bryan Stubbs (Regional Medical Physics Uniit, Cookridge Hospital, Leeds, LS16 6QB) The Management of Tumour Localization for Radiotherapy [Summary] Tumour localization in radiotherapy is considered as the whole process from the actual localization through treatment planning and field checking to the treatment itself. Typical schemes were discussed for head and neck and pelvic tumours and likely sources of error indicated. The importance of maintaining accuracy into the treatment stage is stressed as so often the initial localization and planning receive far more attention than the treatment set-up itself. Reliable information concerning the accuracy of the set-up is difficult to obtain, although Van de Geign (1972) has attempted to record consistency of set-up using a television camera system. His results as yet are not encouraging due to instability in the television imaging system.
Computer control in the treatment process was discussed and felt to be useful for checking some treatment parameters. However, completely automated treatment set-up systems would need to prove themselves in a very positive way to warrant their introduction as their associated disadvantages are considerable. The greatest of these is that the therapy radiographer would hand over a large part of her responsibility to a noni-thinking computer system. Radioisotope organ scanning is being used on an increasing scale as a diagnostic procedure. Probably a majority of such investigations are used to delineate primary or secondary neoplasms. This field of investigation is becoming more specific and accurate with changes of techniques, and I propose to review four areas where there have been recent advances which seem to me of significance to radiotherapists.
REFERENCE
The first area is in radioisotope bone scanning. The traditional assessment of the skeleton for possible metastatic tumour involvement is by a radiological skeletal survey. This, however, is known to be relatively insensitive since a considerable amount of bone destruction may occur before it is radiologically visible. It has been shown that radioisotope bone scanning will indicate areas of new bone formation in the region of metastatic deposits before they are visible on X-rays (Charkes et al. 1964 , Galasko et al. 1968 ). The use of such a diagnostic survey will obviously result in a different staging of tumours. Nevertheless, bone scanning is not widely practised in this country. This is in part due to lack of suitable detecting instruments but also due to lack of a suitable, readily available isotope which will allow examination of the whole skeleton. Fluorine-18 answers this purpose, but is at the moment only available near a cyclotron.
Subramanian & McAfee (1971) described a new bone scanning agent, a complex of tripolyphos- phate which could be labelled with technetium (99Tcn'). The radioisotope 99Tcm is widely available and already in use for a large variety of organ scans. A number of other phosphate compounds have since been described and tested clinically. Fig I shows one such compound, a polyphosphate which has been used to obtain views of the dorsal spine and ribs of a patient with bony metastases. The ease of preparation of these compounds and the wide availability of 99Tcm will undoubtedly mean that bone scanning can be used on a much larger scale than hitherto.
A second organ commonly examined by radioisotope scanning for metastatic disease is the liver. The usual technique employs a radioactive colloid to produce a 'map' of the reticuloendothelial system. Defects, or 'cold areas' represent liver replacement. Such liver replacement representing metastatic deposits, however, can be over 4 cm in diameter and still invisible due to overlying normal liver. This results in inaccuracies due to false negative scans and two approaches can be made to this problem: one by improved instrumentation such as tomographic scanners and cameras and the other by a change of radioisotope such that there is a positive uptake by tumour. Fig 2 shows a conventional colloid liver scan demonstrating defects due to liver replacement by metastatic growth. A scan of the same liver using Gallium-67 (67Ga) shows areas of increased activity representing local uptake in neoplastic tissue. Unfortunately, with this isotope positive uptake in metastatic tumour is seen in only about 50 % of cases, although primary tumours of the liver show a much higher success rate. The most common form of radioisotope organ scan is the brain scan. Here changes of the blood brain barrier caused by either primary or metastatic tumour cause an increase of radioactivity. Such appearances, however, are not specific for neoplasm but may be seen in brain infarcts and a variety of other lesions. The scan can be made more specific by taking rapid sequential views of the brain while a bolus of radioactivity passes through it. By this means, areas of grossly decreased or delayed blood flow due to arterial occlusion can be picked up and these contrast with the normal or increased vascularity present in most tumours.
Changes in instrumentation may also improve detection rate. Glass et al. (1973) have described a scanner utilizing lithium-drifted germanium instead of a sodium iodide detector. Using this instrument Tan, Hudson, Johnston, Glass & Lavender (1973, unpublished) have found an increase in the number of positive scans compared with conventional instrumentation.
All the techniques so far mentioned depend on nonspecific mechanisms for localizing neoplasia. Thus the bone scan depends on new bone formation in the region of metastases; the liver scan on the displacement of reticulo-endothelial cells; and the brain scan on a change in the blood brain barrier. Therefore, all these procedures are liable to 'false positive' in that nonmalignant lesions may cause similar appearances. Since the early days of radioisotope scanning, a search has been made for a tumour-localizing agent; that is, a radiopharmaceutical which would result in increased intracellular levels of Fig 4 " 'In-labelled bleomycin scan ofa ratient with ovarian carcinoma. Activity is seen in the liver and spinal bone marrow and also in the neoplasm in the left ofthe pelvis (arrow) radioactivity compared with normal cells. Edwards & Hayes (1969) stimulated renewed interest in this subject when they described the tumour-localizing properties of 67Ga. Since then a number of centres have used 67Ga in various malignant conditions and it has become apparent that the success rate of such scanning varies with different pathologies. In carcinoma of the bronchus, for example, the majority of lesions show increased activity. Fig 3 shows the chest X-ray and 67Ga scan in a patient with a known carcinoma of the bronchus. In Hodgkin's disease, particularly with mediastinal involvement, success rate is quite high, and in these two diseases gallium scanning may well have a place in the investigation of patients.
These results have also stimulated further research for other tumour-localizing agents.
Indium-111 ("'In) has been suggested, but investigations by our own workers have shown poor clinical and experimental results with "lInchloride when compared with 67Ga (Merrick et al. 1973) . A new principle in tumour-localizing agents was, however, suggested in a report by Nouel et al. (1972) . These workers used the Japanese cytotoxic drug bleomycin labelled with cobalt-57 and this resulted in scans showing good localization of both primary and metastatic tumour. Following this publication workers at the MRC Cyclotron Unit, Hammersmith Hospital, had labelled bleomycin with "'In and this agent is being assessed clinically and experimentally. Fig 4 shows an example of a scan using this agent.
The partial success with all these tumourlocalizing radioisotopes leads to the hope of finding an even better localizing agent that may eventually differentiate groups of abnormal cells by their specific uptake and this, added to our present armamentarium of organ scanning methods, would represent a real advance in diagnostic skills.
Mr W M Ross (Newcastle General Hospital, Newcastle tllpOf Tyne, NE4 6BE)
Summing Up
The three papers presented on tumour localization have approached the subject in very different ways, indicating the complexity of the problem as it affects the daily work of the radiotherapist.
Dr Eddleston referred to the importance of defining the edge of a tumour so that the radiotherapist has a boundary, outside which he can add his margin of apparently normal tissue, to describe the eventual volume to be irradiated. At this point other considerations, such as the radiological nature of the lesion and its natural history, should be taken into account. Dr Eddleston stressed the importance and possibility of exploiting and amplifying the differences at the boundaries between tissues of different densities which produce changes in contrast on the radiographic plate. This arises where soft tissues abut on either bone or an air-containing cavity, in situations where contrast media can be introduced into either the normal or the abnormal tissues, and with radiographic techniques designed to derive maximum information from minor differences in density. One such technique is tomography, which is widely used; Dr Eddlestone described several different forms of it, each with a different application and stated that transverse axial tomography is particularly valuable in the mediastinum, for example, to outline the extent of lymph node involvement by bronchogenic carcinoma. He also referred to stereoscopy in the defining of soft-tissue shadows related to bony structures, as in the base of the skull, and in full evaluation of lymphangiography where nodes may be superimposed on one another in plain films. Dr Eddleston also mentioned that serial views of a lymphangiogram might give information regarding metastatic disease which was not available in the initial film. Dr Lavender concentrated mainly on the detection or elimination of possible metastatic deposits by radioactive isotope scanning methods. He emphasized that the majority of such methods are negative rather than positive, tending to show tumours as areas of depressed uptake of the isotope, and also that it may be difficult to distinguish vascular lesions from tumours. He also described the evolution of some scanning methods for screening purposes, as in the search for latent or occult bone metastases in apparently early tumours. To illustrate this point he traced the increasing sensitivity from radiological skeletal survey through the use of (a) strontium-85 or strontium-87, which is a very slow method; (b) fluorine-18, available only in close proximity to a cyclotron; and (c) technetium-labelled polyphosphates which enable a rapid survey of the skeleton to be made. He showed how techniques should be reviewed regularly; for instance, in the differentiation of vascular lesions from neoplasms of the brain, a rapid series using the gamma camera may give information not available from a scanner. For the future he expects better results from germanium semi-conductors than from the present sodium iodide crystals; he hopes that substances like gallium will prove to be taken up specifically in some tumours; and he looks for improvements in radiopharmaceuticals which may be more specific, for example, bleomycin labelled with cobalt-57 or indium-1l1.
Dr Stubbs emphasized that the problems were not finished whzn the diagnosis was complete and that the tumour volume so defined must then be incorporated in an accurate treatment plan, the first step of which is to relate it to a fixed point either on or related in a known way to the body surface, such as the top of the treatment couch.
Having described the steps necessary to achieve a treatment plan he described the checks which were then required, primarily geometrical checks on the congruence of the planning and treatment set-ups, and radiation checks, using thermoluminescent dosimetry, or doses received on both sides of the edges of the treated volume. In conclusion he raised the question of automatic checking of the parameters at each treatment visit.
